Dogwood Therapeutics, Inc. · NASDAQ:DWTX

Dogwood Therapeutics — Investor Presentation (January 2025)

18 slides from Dogwood Therapeutics's investor presentation, January 2025

  1. Slide 1: Dogwood Therapeutics Corporate Overview Q1 2025

    Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”) Corporate Overview Q1 2025 Developing Non-opioid, Nav 1.7 Specific Sodium Channel Inhibitors to Treat Cancer Related Pain

  2. Slide 2: Forward-Looking Statements and Disclaimers

    Forward-Looking Statements and Disclaimers Forward-Looking Statements  Statements in this presentation contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, othe

  3. Slide 3: DWTX Led by an Experienced Team with Extensive Drug Development Experience

    DWTX Led by an Experienced Team with Extensive Drug Development and Commercialization Experience DWTX Executive Team Management’s Brand Development & Commercialization Experience Includes: Greg Duncan Chairman & CEO R. Michael Gendreau Angela Walsh MD, PhD CMO CFO Ralph Grosswald Meng Zhou SVP of Op

  4. Slide 4: Dogwood Therapeutics Summary

    Dogwood Therapeutics Inc. (NASDAQ: DWTX) Summary  A late-stage clinical development company advancing novel pain management and antiviral therapies, poised to address today’s unmet medical needs: Target indication Candidate Preclinical Phase 1 Phase 2 Phase 3 Chemotherapy-Induced Halneuron® NaV 1.7

  5. Slide 5: Halneuron is a Voltage-Gated Sodium Channel Modulator that Reduces Chronic Pain

    Halneuron® is a Voltage-Gated Sodium Channel Modulator that Reduces Chronic Pain  NAVs are crucial to action potential propagation and pain signal transmission3  NAV 1.7 is associated with certain neuropathies4  Halneuron is a potent small molecule found in puffer fish and several other animals (

  6. Slide 6: Preclinical Efficacy of Halneuron in Rat Oxaliplatin-induced Neuropathic Pain Study

    Preclinical Efficacy of Halneuron® in Rat Oxaliplatin-induced Neuropathic Pain Study Halneuron Effect on PWT in Oxaliplatin inducedInduced Rat Pain Model  Adult male Sprague-Dawley rats. Effect of TTX on 1h PWT in Oxaliplatin pain model rats Placebo 1 ml/kg, sc  Oxaliplatin 4 mg/kg, injected intra

  7. Slide 7: Halneuron Reduces Pain in Both CRP and CINP Patients

    Halneuron® Treatment Demonstrates Reduction of Pain in Both Cancer Related Pain (CRP) and Chemotherapy-Induced Neuropathic Pain (CINP) Patients CINP Phase 2a Signal Seeking CRP Phase 2 Study (n=165) Study (n=125) • Tested for efficacy and safety of • Primarily a dose finding trial Halneuron for mode

  8. Slide 8: Statistically Significant Pain Reduction in Phase 2 Cancer Related Pain Study

    Halneuron® Treatment Demonstrates Statistically Significant Pain Reduction in Phase 2 Cancer Related Pain Study (n=165) Screening Baseline Treatment Early Follow- Late Follow- Long term Injections Up up Follow-Up Days -28 to -7 Days -7 to 0 Days 1-4 Days 5-8 Days 15 Every other visits week CRP Phase

  9. Slide 9: Long Duration of Pain Relief for Initial Responders

    Cancer Related Phase 2 Pain Study (n=165): Long Duration of Pain Relief for Initial Responders Duration of response assessed for initial responders (30% or greater reduction):  After a single cycle of treatment, Halneuron initial responders (50.8% of treated) showed a greater duration of pain reduc

  10. Slide 10: Halneuron Treated Patients Reported Improvement in Pain Compared to Placebo

    Halneuron® Treated Patient Reported an Improvement in Pain Compared to Placebo Treated Patients with CRP (n=165) 100% No. of times ®1 Halneuron Placebo 2 better than 90% Placebo Missing 80% Very Much Improved 12% 2% 6X Very much worse 70% Much Improved 20% 10% 2X Much worse 60% Minimally improved 23

  11. Slide 11: CINP Phase 2a Dose-Ranging Study Highlights

    Halneuron® CINP Phase 2a (n=125) Dose-Ranging Study Highlights CINP Phase 2a Study Assessing Three Doses and Two Dose Regimens, Demonstrates: Halneuron high doses delivered greater pain reduction as compared to low doses Halneuron QD dose pain reduction comparable to BID dose, but exhibited better

  12. Slide 12: Halneuron Exhibits an Acceptable Safety Profile

    Halneuron® Exhibits an Acceptable Safety Profile Ten most frequent Adverse Events for Proposed Phase 2b Phase 2 CINP Trial Clinical Safety Summary (n=165): QD Dose Regimen1 • Majority of AEs were mild to moderate in severity 30 µg QD Placebo • Most common AEs were expected and resolved Adverse Event

  13. Slide 13: Proposed Halneuron 4-Week Phase 2b CINP Study Under Review at FDA

    Proposed Halneuron 4-Week Phase 2b CINP Study Under Review at FDA Baseline Week 1 Week 2 Week 3 Week 4 Run-in Period Avg. of Halneuron 8 injections dosed over 2 weeks Primary Endpoint NRS Days -7 to -1 Pain Recall  Primary Objective of the 4-Week Phase 2b study  To explore the safety and efficacy

  14. Slide 14: Ability to Effectively Treat CINP Portends a Large Market Opportunity

    Ability to Effectively Treat CINP Portends a Large Market Opportunity Commercial Opportunity Highlights  Chemotherapy is effective, but common side effects, include fever, fatigue, infection hair loss and both acute and chronic pain  Platinum/taxane chemotherapy responsible for 70% of CINP  Appro

  15. Slide 15: Halneuron is a Non-opioid, Pain Treatment Development Candidate

    Halneuron® is a Non-opioid, Pain Treatment Development Candidate Novel Nav 1.7 voltage-gated sodium channel inhibitor therapeutic o Highly differentiated, non-opioid mechanism of action to treat pain o Validated pain reduction mechanism supported by decades of scientific research o Extensive preclin

  16. Slide 16: Combination Antiviral Programs

    Combination Antiviral Programs 16

  17. Slide 17: Novel Combination Antiviral Program Targets Two Areas of Unmet Medical Need

    Novel Combination Antiviral Program Targets Two Areas on Unmet Medical Need  Two novel, late-stage clinical stage development assets:  IMC-1 (famciclovir + celecoxib) ready for Phase 3 development as treatment for FM:  FDA agreement to enter Phase 3 post EoP2 meeting; • Pharmacokinetic/Food Effec

  18. Slide 18: Pipeline Has Significant Value Creation Potential Over the Next 12 Months

    Dogwood Therapeutics, Inc. Pipeline has Significant Value Creation Potential Over the Next 12 Months Candidate/ Target Indication Next Key Milestone Target Fibromyalgia IMC-1 Antiviral Phase 3 Partnership Update 1H Long-COVID/ PASC IMC-2 Antiviral Q2 Phase 2b Funding Update CINP Phase 2b Q1: First P

Dogwood Therapeutics — Investor Presentation (January 2025) on 6ix